Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 1
2013 1
2014 1
2017 5
2018 2
2019 7
2020 9
2021 9
2022 5
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer.
Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U. Gardner FP, et al. Among authors: fountzilas c. Cancers (Basel). 2024 Mar 28;16(7):1323. doi: 10.3390/cancers16071323. Cancers (Basel). 2024. PMID: 38611000 Free PMC article.
A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM, Zonneville J, Naranjo MN, Serio H, Melendy T, Straubinger RM, Gillard B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV. Alruwaili MM, et al. Among authors: fountzilas c. Cell Rep Med. 2024 Mar 19;5(3):101434. doi: 10.1016/j.xcrm.2024.101434. Epub 2024 Feb 21. Cell Rep Med. 2024. PMID: 38387463 Free PMC article.
Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma.
Fountzilas C, Velasco SA, Bshara W, LeVea CM, Gupta M, Ji W, George A, Attwood K, Iyer RV. Fountzilas C, et al. J Gastrointest Oncol. 2023 Oct 31;14(5):2192-2201. doi: 10.21037/jgo-23-115. Epub 2023 Sep 15. J Gastrointest Oncol. 2023. PMID: 37969829 Free PMC article.
Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Achutan Pillai SM, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: fountzilas c. Oncotarget. 2023 Oct 19;14:890-892. doi: 10.18632/oncotarget.28530. Oncotarget. 2023. PMID: 37861386 Free PMC article. No abstract available.
Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence.
Li F, Ling X, Chakraborty S, Fountzilas C, Wang J, Jamroze A, Liu X, Kalinski P, Tang DG. Li F, et al. Among authors: fountzilas c. J Exp Clin Cancer Res. 2023 Aug 19;42(1):213. doi: 10.1186/s13046-023-02787-x. J Exp Clin Cancer Res. 2023. PMID: 37596619 Free PMC article. Review.
Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer.
Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, Attwood K, George M, Rempinski D, Franco-Barraza J, Seshadri M, Parker MD, Cortes Gomez E, Fountzilas C, Cukierman E, Steele NG, Feigin ME. Cornwell AC, et al. Among authors: fountzilas c. Clin Cancer Res. 2023 Sep 15;29(18):3793-3812. doi: 10.1158/1078-0432.CCR-23-0547. Clin Cancer Res. 2023. PMID: 37587561 Free PMC article.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. Friedlander M, et al. Among authors: fountzilas c. Br J Cancer. 2023 Sep;129(5):797-810. doi: 10.1038/s41416-023-02349-0. Epub 2023 Jul 20. Br J Cancer. 2023. PMID: 37474720 Free PMC article. Clinical Trial.
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Chiorean EG, et al. Among authors: fountzilas c. J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. doi: 10.6004/jnccn.2023.0034. J Natl Compr Canc Netw. 2023. PMID: 37433437
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D, Hanni S, Serritella AV, Fountzilas C, Michalek J, Hernandez B, Sarantopoulos J, Datta P, Romero O, Pillai SMA, Kuhn J, Pollak M, Thompson IM. Mahalingam D, et al. Among authors: fountzilas c. Oncotarget. 2023 Jun 19;14:622-636. doi: 10.18632/oncotarget.28458. Oncotarget. 2023. PMID: 37335291 Free PMC article. Clinical Trial.
55 results